Key result
Ramipril decreased mortality to 56% compared with 78% for hydralazine and 82% for control in spontaneously hypertensive rats post-myocardial infarction.
Why the study?
Does ramipril improve survival and reduce ventricular arrhythmias in spontaneously hypertensive rats post-myocardial infarction compared to hydralazine or control?
RCT (n=136)
randomized
Does ramipril improve survival and reduce ventricular arrhythmias in spontaneously hypertensive rats post-myocardial infarction compared to hydralazine or control?
In a hypertensive rat model of myocardial infarction, the ACE inhibitor ramipril, but not the direct vasodilator hydralazine, significantly improved survival and reduced ventricular arrhythmias, left ventricular hypertrophy, and cardiac fibrosis.
Answers are grounded in this paper and cite their sources.
Ramipril lowers post-MI mortality more than equivalent BP reduction with hydralazine in SHR; leaves open translation of ACEI antifibrotic effects to human hypertensive LVH.
BACKGROUND: Hypertensive patients with left ventricular hypertrophy (LVH) have been found to have greater peri-infarction and postinfarction mortality. In this study, we evaluated the postinfarction survival, susceptibility to ventricular arrhythmias, and degree of LVH and cardiac fibrosis in the spontaneously hypertensive rat (SHR) and the effects of the ACE inhibitor ramipril and the direct vasodilator hydralazine on these characteristics. METHODS AND RESULTS: An acute myocardial infarction (MI) was produced by ligation of the left anterior descending coronary artery. Rats were randomized to either control (n=50), hydralazine (n=41), or ramipril (n=45). Treatments were started 4 hours after infarction and continued for 8 weeks. Ramipril and hydralazine reduced arterial pressure similarly. Medications were stopped 72 hours before euthanasia, at which time hemodynamic, programmed electrophysiological stimulation (PES), and morphological studies were performed. Mortality was decreased in ramipril (56%) compared with hydralazine (78%) and control (82%) SHRs (P=0.008). This was accompanied by a decrease in myocardial hypertrophy and fibrosis and a decrease in inducibility of ventricular arrhythmias by PES in the ramipril group regardless of MI size. Treatment with hydralazine had little or no effect on LVH and cardiac fibrosis and did not modify inducibility of ventricular arrhythmias by PES. Ramipril but not hydralazine prevented the increase in LV end-diastolic pressure in rats with large MIs. CONCLUSIONS: In the SHR, the ACE inhibitor ramipril reduces LVH, cardiac fibrosis, and susceptibility to ventricular arrhythmias by PES and improves survival and LV function. Despite a similar decrease in arterial pressure, hydralazine does not have these beneficial effects.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (1998) conducted an RCT in Acute myocardial infarction with hypertension and left ventricular hypertrophy (n=136). Ramipril vs. Hydralazine or control was evaluated on Mortality (p=0.008). Ramipril decreased mortality to 56% compared with 78% for hydralazine and 82% for control in spontaneously hypertensive rats post-myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: